ROCKVILLE, Md., Aug. 16, 2011 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) has received a $5 million payment from Fresenius USA Manufacturing, Inc. (Fresenius) that was triggered by the first commercial sale of Phoslyra, a milestone under the agreement governing the Company’s 2006 sale of PhosLo® (calcium acetate) and related assets to Fresenius. These assets included the rights to a new liquid formulation of PhosLo that Fresenius has commercialized as Phoslyra
